

THE RISK OF LIVING LONGER

Thank you for joining us –
the webinar will start shortly



Douglas and Uli ask the ultimate question of human longevity for financial institutions:

How long can we go?



Season 5

Session 1 March 4 th , 2026	The GLP-1 effect: <i>The potential impact of anti-obesity medication on longevity</i>	Ashley Campbell (Crystallise); Mia Marcellus (Club Vita); Daniel Meier (Swiss Re); Richard Russell (RGA); Tristan Walsh (Munich Re)	Recording here
Session 2 May 12 th , 2026	<i>A view from the frontier of cancer research</i>	• Dr Dani Skirrow, Cancer Research UK	Today!

For full details and recordings from other sessions in the series,
visit: www.clubvita.net/us/events/event-recordings or follow <http://linkedin.com/company/club-vita>

THE RISK OF LIVING LONGER

A view from the Frontier of Cancer Research

Today's panel:




Douglas Anderson
(Chair)
Club Vita



Ulrich Stengele
(Chair)
Nationwide Financial




Dr Dani Skirrow
Cancer Research UK



Poll question







“Where do you think the biggest gains in Cancer outcomes will come from?”

- *Improved prevention*
- *Earlier detection*
- *Better treatments*



Causes of death over time

(Age standardised deaths per 100,000, ages 65+)



— Circulatory disease
 — Respiratory disease
 — Cancers
 — Other causes (exc. COVID)
 — COVID (inc. SARS)

Improvement components (driver based approach)

Image from:


[Mortality trends driving life expectancy in insurance, Swiss Re Institute, p15](#)

**Questions
to ask?**

How likely?


Peak impact?

When and where
available?



Agenda


1. Background: *progress so far*
2. Learning from super-avoiders
3. Precision prevention
4. Prediction and detection
5. Targeted longer lasting treatments
6. Discussion




1. Background

*Progress amid a
growing challenge*

We've helped double UK cancer survival



All Cancers (C00-C97), European Age-Standardised Mortality Rates per 100,000 Persons, UK, 1971-2024



A growing global challenge

Now

Cases



18.7 million

Deaths



9.7m million

2045

Cases



30.2 million


Deaths



16.8 million

2. Learning from
'super-avoiders' so
more people can stay
cancer free

Cancer cases start to drop in the 'oldest old'




Super-avoiders

All cancers excluding non-melanoma skin cancer (C00-97 excl. C44). Age-specific incidence rates per 100,000 population, UK, 2017-19. Source: cruk.org/stats

Team ATLAS



Super-avoiders




More information here: [ATLAS | Cancer Grand Challenges](#)

3. Precision prevention

*How we're stopping
some people from
ever getting cancer*

1980s**4,800 cases****now****3,400 cases**

Cervical Cancer (C53), European Age-Standardised Incidence Rates per 100,000 Women, UK, 1993-2021



90%
reduction

**Women now
in their 20s,
offered the
vaccine at
age 12-13**

0 cases



Image from:

<https://ourworldindata.org/hpv-vaccination-world-can-eliminate-cervical-cancer>

future





The first
preventative
lung cancer
vaccine

4. Prediction and detection

*How we're
anticipating cancer to
intervene early*

Detecting cancer at
an early stage saves
lives

Diagnosed at earliest stage (stage 1)



More than 6 in 10

Diagnosed at latest stage (stage 4)



Less than 1 in 10



Around 9 in 10



Around 1 in 10

Lung



Bowel



Galleri – the results

No reduction in later stage cancers diagnosed

But

- Fewer found at stage 4
- More detected
- More found early



Detecting one
mutant in a
million pieces
of DNA



Using platelets
to increase DNA
concentration




Nanopore
sequencing to
read errors

Cancer prediction



Detect more
cancers earlier



More targeted
testing



Risk prediction
needs innovation



Data science
holds the answer

Inside CD3




Health, family
history, genes,
socioeconomics,
lifestyle



Statistics,
artificial
intelligence




Screening and
symptomatic
testing




5. Targeted, longer-lasting treatments

*How we're improving treatments so
people stay cancer free for longer*



Our research has played a role in **more than half** of the world's essential cancer drugs.




8 in 10 people prescribed cancer drugs on the NHS receive a drug linked to our research.

Immunotherapy transformed skin cancer survival

2010



now



THE RISK OF LIVING LONGER

A view from the Frontier of Cancer Research

Questions?



Douglas Anderson
(Chair)
Club Vita



Ulrich Stengele
(Chair)
Nationwide Financial



Dr Dani Skirrow
Cancer Research UK

Thank you

This presentation contains information and materials proprietary to Club Vita US LLC (CV). CV are the owner or the licensee of all intellectual property rights in the presentation. All such rights are reserved. The material and charts included herewith are provided as background information for illustration purposes only. This presentation is not a definitive analysis of the subjects covered and should not be regarded as a substitute for specific advice in relation to the matters addressed. It is not advice and should not be relied upon. This presentation should not be released or otherwise disclosed to any third party without prior consent from CV. CV accept no liability for errors or omissions or reliance upon any statement or opinion herein.